Skip to main content
Premium Trial:

Request an Annual Quote

Fluxion, Stanford Co-Developing Tests for CTCs

NEW YORK (GenomeWeb News) – Fluxion Biosciences said today it is collaborating with the Stanford University School of Medicine to develop tests to help tailor treatments for cancer patients.

As part of the partnership, the laboratory of Stefanie Jeffrey, a professor at the Stanford Cancer Institute, will use Fluxion's IsoFlux System to isolate, recover, and analyze rare circulating cancer cells. The microfluidic system isolates rare cancer cells and provides a real-time "liquid biopsy" of samples for molecular analysis, the South San Francisco, Calif.-based company said. The system installed in Jeffrey's lab targets applications that include mutational analysis and cancer cell culturing.

The collaboration will focus on breast and lung cancer with a goal of subtyping different forms of the disease and developing treatments personalized to each individual patient.

Financial and other terms of the deal were not disclosed.

Earlier this month Fluxion reached an agreement with Rubicon Genomics to integrate enrichment methods for circulating tumor cells using the IsoFlux system and Rubicon's NovaPlex sample preparation kits.